Beigene Ltd
NASDAQ:ONC

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
NASDAQ:ONC
Watchlist
Price: 338.81 USD -0.83% Market Closed
Market Cap: $472.3B

Operating Margin

2.9%
Current
Improving
by 49.1%
vs 3-y average of -46.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.9%
=
Operating Income
¥1B
/
Revenue
¥35.7B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.9%
=
Operating Income
$1B
/
Revenue
¥35.7B

Peer Comparison

Country Company Market Cap Operating
Margin
KY
Beigene Ltd
SSE:688235
258.2B CNY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Cayman Islands
Percentile
50th
Based on 101 companies
50th percentile
2.9%
Low
-16 672.6% — -2.9%
Typical Range
-2.9% — 10.1%
High
10.1% — 125.7%
Distribution Statistics
Cayman Islands
Min -16 672.6%
30th Percentile -2.9%
Median 2.9%
70th Percentile 10.1%
Max 125.7%

Beigene Ltd
Glance View

Market Cap
472.3B USD
Industry
Biotechnology

BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.

ONC Intrinsic Value
246.39 USD
Overvaluation 27%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
2.9%
=
Operating Income
¥1B
/
Revenue
¥35.7B
What is Beigene Ltd's current Operating Margin?

The current Operating Margin for Beigene Ltd is 2.9%, which is above its 3-year median of -46.2%.

How has Operating Margin changed over time?

Over the last 3 years, Beigene Ltd’s Operating Margin has increased from -156% to 2.9%. During this period, it reached a low of -156% on Aug 30, 2022 and a high of 2.9% on Oct 30, 2025.

Back to Top